VOR Stock Price, Vor Biopharma Inc. Quote, Chart

Market Summary

USD1.76-0.01

Market Closed

-0.56%

VOR Stock Price

View Fullscreen

VOR RSI Chart

VOR Valuation

Market Cap

120.0M

Price/Earnings (Trailing)

-1.02

Price/Free Cashflow

-1.18

VOR Price/Earnings (Trailing)

VOR Profitability

Return on Equity

-78.2%

Return on Assets

-59.49%

Free Cashflow Yield

-84.48%

VOR Fundamentals

VOR Earnings

Earnings (TTM)

-117.9M

Earnings Growth (Yr)

-9.83%

Earnings Growth (Qtr)

20.88%

Breaking Down VOR Revenue

Last 7 days

3.5%

Last 30 days

-15.8%

Last 90 days

-20.7%

Trailing 12 Months

-55.3%

How does VOR drawdown profile look like?

VOR Financial Health

Current Ratio

9.04

VOR Investor Care

Shares Dilution (1Y)

75.36%

Diluted EPS (TTM)

-1.75

Tracking the Latest Insider Buys and Sells of Vor Biopharma Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 01, 2024	jorgensen nathan d.	sold (taxes)	-14,323	2.27	-6,310	chief financial officer
Mar 01, 2024	chakraborty tirtha	sold (taxes)	-12,657	2.27	-5,576	chief scientific officer
Mar 01, 2024	ang robert	sold (taxes)	-28,731	2.27	-12,657	president and ceo
Feb 06, 2024	jorgensen nathan d.	sold (taxes)	-2,285	2.32	-985	chief financial officer
Feb 06, 2024	chakraborty tirtha	sold (taxes)	-2,396	2.32	-1,033	chief scientific officer
Feb 06, 2024	attar eyal c.	sold (taxes)	-2,737	2.32	-1,180	chief medical officer
Feb 06, 2024	ang robert	sold (taxes)	-6,468	2.32	-2,788	president and ceo
Jan 29, 2024	jorgensen nathan d.	acquired	-	-	50,000	chief financial officer
Jan 29, 2024	chakraborty tirtha	acquired	-	-	53,750	chief scientific officer
Jan 29, 2024	attar eyal c.	acquired	-	-	62,500	chief medical officer

Which funds bought or sold VOR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	MONEY CONCEPTS CAPITAL CORP	new	-	47,400	47,400	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	14.00	14.00	-%
Apr 25, 2024	Chicago Partners Investment Group LLC	added	4.24	-6,587	33,942	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-1,000	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-3.38	4,317	247,787	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.35	-4,000	3,000	-%
Apr 19, 2024	BOURGEON CAPITAL MANAGEMENT LLC	unchanged	-	3,534	69,797	0.01%
Apr 17, 2024	GRIMES & COMPANY, INC.	added	3.35	2,724	33,450	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	156	230,630	366,013	0.01%

Are Funds Buying or Selling VOR?

Are funds buying VOR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VOR

No. of Funds

Unveiling Vor Biopharma Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	5am ventures vi, l.p.	6.8%	4,595,089	SC 13D/A
Feb 14, 2024	paradigm biocapital advisors lp	9.5%	6,457,293	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Aug 11, 2023	ra capital management, l.p.	33.7%	22,780,343	SC 13D/A
Feb 14, 2023	paradigm biocapital advisors lp	9.9%	6,477,999	SC 13G/A
Jan 10, 2023	fmr llc	-	0	SC 13G/A
Dec 09, 2022	ra capital management, l.p.	34.8%	22,760,145	SC 13D/A
Nov 14, 2022	ra capital management, l.p.	28.78%	11,131,300	SC 13D/A
Oct 27, 2022	paradigm biocapital advisors lp	6.1%	2,328,494	SC 13G
Feb 09, 2022	fmr llc	-	0	SC 13G/A

Recent SEC filings of Vor Biopharma Inc.

View All Filings

Date Filed	Form Type	Document
May 02, 2024	3	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	8-K	Current Report
May 02, 2024	DEFA14A	DEFA14A
Apr 09, 2024	ARS	ARS
Apr 09, 2024	DEF 14A	DEF 14A
Apr 09, 2024	DEFA14A	DEFA14A
Mar 21, 2024	S-8	Employee Benefits Plan
Mar 20, 2024	10-K	Annual Report
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to Vor Biopharma Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Vor Biopharma Inc. News

Latest updates

Vor Biopharma Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-11.2%	198	223	251	278	299	206	225	234	243	259	275	293	76.00
Current Assets	-14.4%	141	164	191	217	237	143	159	190	214	232	249	266	49.00
Cash Equivalents	-30.4%	31.00	45.00	32.00	42.00	58.00	61.00	63.00	90.00	120	143	170	263	49.00
Net PPE	-7.2%	10.00	11.00	11.00	12.00	13.00	13.00	15.00	12.00	7.00	6.00	6.00	6.00	5.00
Liabilities	-1.7%	47.00	48.00	47.00	47.00	49.00	48.00	50.00	40.00	26.00	26.00	25.00	26.00	28.00
Current Liabilities	1.2%	16.00	15.00	13.00	13.00	13.00	11.00	12.00	18.00	10.00	9.00	8.00	9.00	10.00
Shareholder's Equity	-13.8%	151	175	204	230	251	159	175	194	216	233	250	267	-
Retained Earnings	-8.4%	-340	-313	-280	-250	-222	-198	-174	-152	-130	-111	-93.32	-74.95	-61.22
Additional Paid-In Capital	0.4%	491	489	486	481	474	358	351	348	346	345	343	342	2.00
Shares Outstanding	0.2%	68.00	68.00	67.00	67.00	66.00	38.00	37.00	37.00	37.00	32.00	37.00	22.00	-
Float	-	-	-	136	-	-	-	116	-	-	-	352	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	13.9%	-24,026	-27,898	-24,100	-24,268	-18,346	-18,902	-24,992	-22,904	-17,587	-17,343	-16,565	-17,649	-13,634	-8,245	-8,328	-6,085
Share Based Compensation	-40.1%	1,894	3,162	4,238	4,068	3,879	3,329	1,741	1,746	1,203	1,154	1,067	891	594	483	153	112
Cashflow From Investing	-74.5%	10,335	40,536	13,639	6,498	-97,036	12,702	-2,702	-7,055	-5,953	-8,486	-76,041	-1,171	-1,477	-1,587	-552	-545
Cashflow From Financing	-85.8%	25.00	176	218	2,519	112,261	4,075	604	200	307	201	-445	232,848	46.00	526	64,192	17,762

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VOR Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 94,315	$ 64,550
General and administrative	31,721	28,868
Total operating expenses	126,036	93,418
Loss from operations	(126,036)	(93,418)
Other income:
Interest income	8,173	1,324
Total other income	8,173	1,324
Net loss	$ (117,863)	$ (92,094)
Net loss per share attributable to common stockholders, basic	$ (1.75)	$ (2.33)
Net loss per share attributable to common stockholders, diluted	$ (1.75)	$ (2.33)
Weighted-average common shares outstanding, basic	67,191,973	39,551,420
Weighted-average common shares outstanding, diluted	67,191,973	39,551,420
Other comprehensive income (loss):
Unrealized gain (loss) on available for sale investments	$ 693	$ (770)
Total other comprehensive income (loss)	693	(770)
Comprehensive loss	$ (117,170)	$ (92,864)

VOR Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 31,360	$ 57,706
Marketable securities	105,815	172,539
Prepaid expenses	3,153	4,368
Other current assets	475	2,337
Total current assets	140,803	236,950
Restricted cash equivalents	2,413	2,413
Property and equipment, net	10,050	12,634
Operating lease right-of-use assets	40,048	44,444
Other assets	4,812	2,925
Total assets	198,126	299,366
Current liabilities:
Accounts payable	815	1,772
Accrued liabilities	10,877	7,889
Operating lease liabilities	3,830	3,272
Other current liabilities	50	186
Total current liabilities	15,572	13,119
Long-term liabilities:
Operating lease liabilities—non-current	31,830	35,640
Total liabilities	47,402	48,759
Stockholders' equity :
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022
Common stock, $0.0001 par value; 400,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 67,901,610, and 66,079,597 shares issued and 67,891,311 and 65,996,138 outstanding as of December 31, 2023 and December 31, 2022, respectively	7	7
Additional paid-in capital	490,874	473,587
Accumulated other comprehensive loss	(77)	(770)
Accumulated deficit	(340,080)	(222,217)
Total stockholders' equity	150,724	250,607
Total liabilities and stockholders' equity	$ 198,126	$ 299,366

About Vor Biopharma Inc.

Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Robert Ang M.B.A., M.D., MBBS
WEBSITE	vorbio.com
INDUSTRY	Biotechnology
EMPLOYEES	133

Vor Biopharma Inc. Frequently Asked Questions

What is the ticker symbol for Vor Biopharma Inc.? What does VOR stand for in stocks?

VOR is the stock ticker symbol of Vor Biopharma Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vor Biopharma Inc. (VOR)?

As of Thu May 02 2024, market cap of Vor Biopharma Inc. is 119.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VOR stock?

You can check VOR's fair value in chart for subscribers.

What is the fair value of VOR stock?

You can check VOR's fair value in chart for subscribers. The fair value of Vor Biopharma Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vor Biopharma Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VOR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vor Biopharma Inc. a good stock to buy?

The fair value guage provides a quick view whether VOR is over valued or under valued. Whether Vor Biopharma Inc. is cheap or expensive depends on the assumptions which impact Vor Biopharma Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VOR.